Delivering Novel Anti-Viral Therapies

to Patients with Weakened Immune Systems


AiCuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS®, marketed by our partner MSD, treats CMV in a defined group of transplant recipients. Our pivotal Phase 3 candidate pritelivir is designed to address recurrent and resistant HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. AiCuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future.

Latest News


AiCuris Announces Milestone Achievements Further Validating its Pipeline of Anti-viral Solutions for Immuno-compromised Patients

AiCuris reached major milestones in 1H 2024 for letermovir (marketed by MSD as PREVYMIS®), pritelivir, and AIC468 highlighting the rapid progress in developing anti-viral solutions for immunocompromised patients.

Read more


AiCuris presents novel data on its candidate AIC468, an antisense oligonucleotide for treatment of BKV infections

Our team has been making waves at the 34th ESCMID Global in Barcelona and the ATC2024 in Philadelphia with lively discussions around impressive AIC468 data at the respective poster sessions.

Read more


„AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement“

The cooperation provides us with the opportunity to combine exceptional German antiviral research with our development capabilities and clinical expertise to develop novel therapies for immunocompromised patients.

Read more


AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS®

PREVYMIS® received european approval for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk.

Read more


AiCuris Senior Management heading to San Francisco for the J.P. Morgan Annual Healthcare Conference from January 8th–11th

Meet with our CEO Larry Edwards and CFO Sabrina Kuttruff-Coqui at the J.P. Morgan Annual Healthcare Conference.

Read more


AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients

Young start-ups and academic teams can apply to the AiCubator program starting from October 1st to December 31st, 2023.

Read more


AiCuris Received €30 Million Milestone Payment from Partner MSD Following U.S. FDA Approval of PREVYMIS® in Second Indication

PREVYMIS® now approved for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk

Read more


AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives Treatments for Immunocompromised Patients

Company will advance its highly differentiated product portfolio, including a proprietary phase 3 candidate with fast track to market.

Read more